Document is current
Any future updates will be listed below
-
Authors
Babalonis, Shanna https://orcid.org/0000-0002-1450-2621
Comer, Sandra D.
Jones, Jermaine D.
Nuzzo, Paul
Lofwall, Michelle R.
Manubay, Jeanne
Hatton, Kevin W.
Whittington, Robert A.
Walsh, Sharon L.
-
Funding
Funding for this research was provided by:
U.S. Food and Drug Administration (HHSF223201710119C, HHSF223201710120C)
National Center for Advancing Translational Sciences (UL1TR001998)
- License Information
-
More Information
Article History
Received: 8 February 2021
Accepted: 5 May 2021
First Online: 1 June 2021
Declarations
:
: In the past three years, Sandra Comer has provided consulting and advisory board services to pharmaceutical and health services companies (Alkermes, Charleston Labs, Clinilabs, Collegium, Epiodyne, Mallinckrodt, Nektar, Opiant, Osmotica, Otsuka, Sun Pharma), her university has received research contracts from companies for drug-related research for which she serves as Principal or Co-Principal Investigator (Alkermes, BioXcel, Corbus, GoMedical, Intra-cellular Therapies, Lyndra, and Janssen), and she received honoraria for writing critical reviews for the World Health Organization. Sharon Walsh has served as a consultant or scientific advisor for Opiant Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Camurus, Otsuka, BrainsWay, Trevi Therapeutics, Summit Biosciences, and World Meds over the past 3 years on topics related to opioid use disorder and its treatment but not directly related to the topic of this report. Jermaine Jones is currently the recipient of an investigator-initiated grant from Merck Pharmaceuticals and has served as a consultant for Alkermes for the past 3 years. Shanna Babalonis, Michelle Lofwall, Kevin Hatton, Jeanne Manubay, Robert Whittington, and Paul Nuzzo have no conflicts to report related to this project.
